Skip to main content
. 2021 Nov 1;13(1):1981202. doi: 10.1080/19420862.2021.1981202

Table 2.

Binding affinities of bemarituzumab and FPA144-F to human FcγRIIIa (V158)

Antibody KD (Koff/Kon) (nM)
FPA144-A (bemarituzumab) 9.2
FPA144-F (the fucosylated version) 207

Kon = associate constant; Koff = dissociate constant; KD = equilibrium dissociation constant.

Surface plasmon resonance was used to determine binding affinities; 5 concentrations (0–1000 nM) of FcγRIIIa (V158) were tested. Kon, Koff, and KD were calculated using the Biacore T100 Evaluation Software 1:1 binding model.